

IDS - 08/20/2002

PATENT & TRADEMARK OFFICE
RICHARD E. JENKINS
JEFFREY L. WILSON
ARLES A. TAYLOR, JR.
DAVID R. GLOEKLER
GREGORY A. HUNT
JOHN A. LANERDIN, Ph.D.
BENTLEY J. OLIVE
E. ERIC MILLS
CHRISTOPHER P. PERKINS, Ph.D.*
*LICENSED ONLY IN CALIFORNIA

JENKINS & WILSON, P.A.
PATENT ATTORNEYS
SUITE 1400 UNIVERSITY TOWER
3100 TOWER BOULEVARD
DURHAM, NORTH CAROLINA 27707
TELEPHONE (919) 493-8000
FACSIMILE (919) 419-0383
WEBSITE
JENKINSANDWILSON.COM

0300 #5 000
COPY OF PAPERS
ORIGINALLY FILED

RALEIGH OFFICE
NCSU CENTENNIAL CAMPUS
VENTURE II SUITE 400
920 MAIN CAMPUS DRIVE
RALEIGH, NORTH CAROLINA 27606
TELEPHONE (919) 424-3710
FACSIMILE (919) 424-3711

August 8, 2002

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Commissioner of Patents and Trademarks, Washington, D.C. on August 8, 2002

Cathi H. Turner
Cathi H. Turner
Date of Signature: August 8, 2002

Commissioner for Patents
Washington, D.C. 20231

Re: U.S. Patent Application Serial No. 10/190,281 for
ATTACK OF TUMOR CELLS WITH MISSING, LOW OR
ABERRANT MHC EXPRESSION BY COMBINING NON
MHC-RESTRICTED T-CELLS/NK-CELLS AND MHC-
RESTRICTED CELLS
Our File No. 1406/81

Sir:

Please find enclosed in connection with the subject U.S. patent application the following documents:


1. Information Disclosure Statement (2 pages);
2. Form PTO/SB/08B (in duplicate) (1 page);
3. Copies of cited references (7 references);
4. A return-receipt postcard to be returned to us with the U.S. Patent and Trademark Office filing stamp thereon.

Commissioner for Patents
Page 2
August 8, 2002

The Commissioner is hereby authorized to charge any fees associated with the filing of this correspondence to Deposit Account No. 50-0426.

Respectfully submitted,

JENKINS & WILSON, P.A.



Richard E. Jenkins
Registration No. 28,428

REJ/haw/cht

Enclosures

Customer No. Bar Code Label:



25297

PATENT TRADEMARK OFFICE



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Commissioner of Patents, Washington, D.C. 20231 on August 8, 2002

Cathi H. Turner
Cathi H. Turner
Date of Signature *August 8, 2002*

PATENT

COPY OF PAPERS
ORIGINALLY FILED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Schendel et al.

Group Art Unit: Not Assigned

Serial No.: 10/190,281

Examiner: Not Assigned

Filed: July 5, 2002

Docket No. 1406/81

Confirmation No.:

For: ATTACK OF TUMOR CELLS WITH MISSING, LOW OR ABERRANT MHC
EXPRESSION BY COMBINING NON MHC-RESTRICTED T-CELL/NK-CELLS
AND MHC-RESTRICTED CELLS

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

In accordance with 37 C.F.R. 1.56, 1.97, and 1.98, applicants' undersigned attorney brings to the attention of the Patent and Trademark Office the following references. Copies of the references as well as Forms PTO/SB/08A and PTO/SB/08B are attached hereto. This is not to be construed as a representation that a search has been made or that a reference is relevant merely because cited.

~ Lifesci 89: 29 815/AN (Abstract zu: Cruse, J.M. et al., EOS-J. Immunol. Immunopharmacol 9 (2), 1989, 41-53)

~ Medline 953 54 186/AN (Abstract zu: Baxeranis, C.N. et al., Lancer Immunology, Immunotherapy 40 (6), 1995, 410-8)

~ Medline 960 65 257/AN (Abstract zu: Schlebusch, H. et al., Hybridoma 14 (2), 1995, 167-74)

~ Medline 920 94 170/AN (Abstract zu: Melief, C.J. et al., Res. Immunol. 142 (5-6), 1991, 425-9)

Medline 971 32 099/AN (Abstract zu: Leong, G.P., Surgical Clinics of North America 76 (6), 1996, 1355-81)

Medline 973 75 563/AN (Abstract zu: Schendel, D.J. et al., J. Mol. Med. 75 (6), 1997, 400-13)

Medline 940 83 459/AN (Abstract zu: Abe, Y. et al., Lymphocyte Cytokine Res. 12 (5), 1993, 279-83)

Early passage of the subject application to issue is earnestly solicited.


Although it is believed that no fee is due, the Commissioner is hereby authorized to charge any deficiencies of payment associated with the filing of this Information Disclosure Statement to Deposit Account No. 50-0426.

Respectfully submitted,

JENKINS & WILSON, P.A.

Date: August 8, 2002

By:


Richard E. Jenkins
Registration No. 28,428

Suite 1400 University Tower
3100 Tower Boulevard
Durham, North Carolina 27707
Telephone: (919) 493-8000
Facsimile: (919) 419-0383

Customer No. Bar Code Label:

1406/81 REJ/haw/cht


Enclosures



25297

PATENT TRADEMARK OFFICE

BEST AVAILABLE COPY



COPY OF PAPERS
ORIGINALLY FILED

PTO/SB/088 (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Complete If Known

Application Number	10/190,281
Filing Date	07/05/2002
First Named Inventor	Dolores Schendel
Group Art Unit	
Examiner Name	
Attorney Docket Number	1406/81

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
KAC	1	CRUSE ET AL., "Immunol Immunopharmacol," Lifesci 89, Vol. 9 (No. 2), p. 41-53, (1989).	
	2	BAXERANIS ET AL., "Lancet Immunology, Immunotherapy," Medline, Vol. 40 (No. 6), p. 410-8, (1995).	
	3	SCHLEBUSCH ET AL., "Hybridoma," Medline, Vol. 14 (No. 2), p. 167-74, (1995).	
	4	MELIEF ET AL., "Res. Immunol," Medline, Vol. 142 (No. 5-6), p. 425-9, (1991).	
	5	G.P. LEONG, "Surgical Clinics of North America," Medline, Vol. 76 (No. 6), p. 1355-81, (1996).	
	6	SCHENDEL ET AL., "Mol. Med.," Medline, Vol. 75 (No. 6), p. 400-13, (1997).	
✓	7	ABE ET AL., "Lymphocyte Cytokine Res.," Medline, Vol. 12 (No. 5), p. 279-83, (1993).	

Examiner
Signature

/Karen A. Canella, Ph.D./

Date
Considered

06/26/2006


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



IDS - 02/18/2003



Bonnie S. Sheridan
Bonnie S. Sheridan
Date of Signature *February 11, 2003*

PATENT
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Schendel et al.

Group Art Unit: 1633

Serial No.: 10/190,281

Examiner: Not Assigned

Filed: July 5, 2002

Docket No. 1406/81

Confirmation No.: 2506

For: ATTACK OF TUMOR CELLS WITH MISSING, LOW OR ABERRANT MHC
EXPRESSION BY COMBINING NON MHC-RESTRICTED T-CELLS/NK-
CELLS AND MHC-RESTRICTED CELLS

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

In accordance with 37 C.F.R. 1.56, 1.97, and 1.98, applicants' undersigned attorney brings to the attention of the Patent and Trademark Office the documents listed on the attached forms PTO/SB/08A and PTO/SB/08B. Copies of the references as well as Forms PTO/SB/08A and PTO/SB/08B are attached hereto. This is not to be construed as a representation that a search has been made or that a reference is relevant merely because cited.

Early passage of the subject application to issue is earnestly solicited.

Although it is believed that no fee is due, the Commissioner is hereby authorized to charge any deficiencies of payment associated with the filing of this Information Disclosure Statement to Deposit Account No. 50-0426.

Respectfully submitted,

JENKINS & WILSON, P.A.

Date: February 11, 2003


By:

Richard E. Jenkins
Richard E. Jenkins
Registration No. 28,428

Suite 1400 University Tower
3100 Tower Boulevard

Customer No. Bar Code Label:

BEST AVAILABLE COPY



Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
 required to respond to a collection of information unless it contains a valid OMB

Substitute for form 1449A/PTO

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number	10/190,281
Filing Date	07/05/2002
First Named Inventor	Dolores Schendel
Art Unit	1633
Examiner Name	Unassigned
Attorney Docket Number	1406/81

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

**Examiner
Signature**

/Karen A. Canella, Ph.D./


Date
Considered

06/26/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/190,281
		Filing Date	07/05/2002
		First Named Inventor	Dolores Schendel
		Group Art Unit	1633
		Examiner Name	Not Assigned
Sheet 1 of 1	Attorney Docket Number	1406/81	

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
KAC	C1	GIORGIO PARMIANI, "An explanation of the variable clinical response to interleukin 2 and LAK cells," Immunology Today, Elsevier Science Publishers Ltd. (UK), Vol. 11 (No. 04), p. 113-115, (1990).	X
KAC	C2	HOFFMAN ET AL., "Adoptive Cellular Therapy," Seminars in Oncology, Vol. 27 (No. 02), p. 221-233, (April 2000).	X
KAC	C3	SCHENDEL ET AL., "Cellular and molecular analyses of major histocompatibility complex (MHC) restricted and non-MHC-restricted effector cells recognizing renal cell carcinomas: problems and perspectives for immunotherapy," J Mol Med, Springer-Verlag, p. 400-413, (1997).	X

Examiner Signature	/Karen A. Canella, Ph.D./	Date Considered	06/26/2006
--------------------	---------------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.